Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Anti-PD-1 antibody
PD-L1 TPS
non-small cell lung cancer
soluble PD-L1
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
19
08
2020
revised:
11
10
2020
accepted:
12
10
2020
pubmed:
28
10
2020
medline:
20
11
2021
entrez:
27
10
2020
Statut:
ppublish
Résumé
Programmed cell death ligand 1 (PD-L1) is known to have soluble forms aside from its membrane-bound forms. The aim of this study was to evaluate the predictive and prognostic values of serum soluble PD-L1 (sPD-L1) in patients with non-small cell lung cancer (NSCLC) who were treated with anti-PD-1 antibody. A total of 233 patients were enrolled in this study. We assessed the level of serum sPD-L1 before anti-PD-1 antibody treatment (pembrolizumab or nivolumab) and evaluated the correlation with PD-L1 expression on tumor cells, the response to anti-PD-1 antibody treatment, and patient outcome. The median serum sPD-L1 concentration was 67.7 (range, 25 to 223) pg/mL. A weak correlation between serum sPD-L1 and tumor PD-L1 expression was observed. The disease control rate in the high sPD-L1 group (≥90 pg/mL) was significantly lower than that in the low sPD-L1 group (<90 pg/mL) (37% vs. 57%, P = 0.0158). The progression-free survival (PFS) and overall survival (OS) in the high sPD-L1 group were significantly shorter than those in the low sPD-L1 group (median PFS, 57 days vs. 177 days, P = 0.011; median OS, 182 days vs. not reached, P < 0.001). The high level of serum sPD-L1 was independently associated with a shorter PFS (hazard ratio [HR], 1.910; P = 0.061) and OS (HR, 2.073; P = 0.034) in multivariate analysis. The serum sPD-L1 level, which was only weakly correlated with the tumor PD-L1 expression level, was an independent predictive and prognostic biomarker for NSCLC patients receiving anti-PD-1 antibody. SIGNIFICANT FINDINGS OF THE STUDY: The disease control rate in the high sPD-L1 group was significantly lower than that in the low sPD-L1 group. The progression-free survival (PFS) and overall survival (OS) in the high sPD-L1 group were significantly shorter than those in the low sPD-L1 group. The high level of serum sPD-L1 was independently associated with a shorter PFS and OS in multivariate analysis. This study demonstrated that serum sPD-L1 level was an independent predictive and prognostic biomarker for NSCLC patients receiving anti-PD-1 antibody.
Sections du résumé
BACKGROUND
Programmed cell death ligand 1 (PD-L1) is known to have soluble forms aside from its membrane-bound forms. The aim of this study was to evaluate the predictive and prognostic values of serum soluble PD-L1 (sPD-L1) in patients with non-small cell lung cancer (NSCLC) who were treated with anti-PD-1 antibody.
METHODS
A total of 233 patients were enrolled in this study. We assessed the level of serum sPD-L1 before anti-PD-1 antibody treatment (pembrolizumab or nivolumab) and evaluated the correlation with PD-L1 expression on tumor cells, the response to anti-PD-1 antibody treatment, and patient outcome.
RESULTS
The median serum sPD-L1 concentration was 67.7 (range, 25 to 223) pg/mL. A weak correlation between serum sPD-L1 and tumor PD-L1 expression was observed. The disease control rate in the high sPD-L1 group (≥90 pg/mL) was significantly lower than that in the low sPD-L1 group (<90 pg/mL) (37% vs. 57%, P = 0.0158). The progression-free survival (PFS) and overall survival (OS) in the high sPD-L1 group were significantly shorter than those in the low sPD-L1 group (median PFS, 57 days vs. 177 days, P = 0.011; median OS, 182 days vs. not reached, P < 0.001). The high level of serum sPD-L1 was independently associated with a shorter PFS (hazard ratio [HR], 1.910; P = 0.061) and OS (HR, 2.073; P = 0.034) in multivariate analysis.
CONCLUSIONS
The serum sPD-L1 level, which was only weakly correlated with the tumor PD-L1 expression level, was an independent predictive and prognostic biomarker for NSCLC patients receiving anti-PD-1 antibody.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: The disease control rate in the high sPD-L1 group was significantly lower than that in the low sPD-L1 group. The progression-free survival (PFS) and overall survival (OS) in the high sPD-L1 group were significantly shorter than those in the low sPD-L1 group. The high level of serum sPD-L1 was independently associated with a shorter PFS and OS in multivariate analysis.
WHAT THIS STUDY ADDS
This study demonstrated that serum sPD-L1 level was an independent predictive and prognostic biomarker for NSCLC patients receiving anti-PD-1 antibody.
Identifiants
pubmed: 33108686
doi: 10.1111/1759-7714.13721
pmc: PMC7705908
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3585-3595Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Transl Oncol. 2018 Jun;11(3):779-785
pubmed: 29698935
Chin J Cancer Res. 2014 Feb;26(1):104-11
pubmed: 24653632
Med Oncol. 2019 Mar 1;36(4):33
pubmed: 30825015
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Oncotarget. 2018 Apr 3;9(25):17554-17563
pubmed: 29707129
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Bull Exp Biol Med. 2019 Jan;166(3):353-357
pubmed: 30627905
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Cancer Immunol Immunother. 2014 Jul;63(7):675-83
pubmed: 24695951
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
J Cancer Res Clin Oncol. 2019 Feb;145(2):303-312
pubmed: 30267213
Inflammation. 2009 Jun;32(3):169-75
pubmed: 19373547
J Cancer Res Clin Oncol. 2016 Aug;142(8):1727-38
pubmed: 27256004
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Immunol Lett. 2012 Feb 29;142(1-2):78-82
pubmed: 22138406
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
Thorac Cancer. 2015 Jul;6(4):534-8
pubmed: 26273411
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
Front Immunol. 2018 Jun 28;9:1474
pubmed: 30002656
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Oncotarget. 2015 Dec 1;6(38):41228-36
pubmed: 26515600
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Br J Cancer. 2002 Jul 29;87(3):264-7
pubmed: 12177792
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902
Oncotarget. 2017 Oct 7;8(61):103117-103128
pubmed: 29262550
Int J Biol Markers. 2015 Nov 11;30(4):e364-8
pubmed: 26349666